Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Goodwill & Intangibles: 2010-2025

Historic Goodwill & Intangibles for Sunshine Biopharma (SBFM) over the last 5 years, with Sep 2025 value amounting to $2.1 million.

  • Sunshine Biopharma's Goodwill & Intangibles fell 30.32% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 30.32%. This contributed to the annual value of $3.1 million for FY2024, which is 117.33% up from last year.
  • Sunshine Biopharma's Goodwill & Intangibles amounted to $2.1 million in Q3 2025, which was down 20.76% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Goodwill & Intangibles peaked at $3.3 million during Q1 2025, and registered a low of $776,856 during Q4 2022.
  • Over the past 3 years, Sunshine Biopharma's median Goodwill & Intangibles value was $2.1 million (recorded in 2024), while the average stood at $2.2 million.
  • Per our database at Business Quant, Sunshine Biopharma's Goodwill & Intangibles surged by 143.58% in 2024 and then plummeted by 30.32% in 2025.
  • Over the past 4 years, Sunshine Biopharma's Goodwill & Intangibles (Quarterly) stood at $776,856 in 2022, then skyrocketed by 85.91% to $1.4 million in 2023, then soared by 117.33% to $3.1 million in 2024, then plummeted by 30.32% to $2.1 million in 2025.
  • Its Goodwill & Intangibles was $2.1 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.3 million in Q1 2025.